1. Home
  2. WSO vs GMAB Comparison

WSO vs GMAB Comparison

Compare WSO & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Watsco Inc.

WSO

Watsco Inc.

HOLD

Current Price

$348.13

Market Cap

14.4B

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$31.74

Market Cap

17.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WSO
GMAB
Founded
1945
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4B
17.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WSO
GMAB
Price
$348.13
$31.74
Analyst Decision
Hold
Strong Buy
Analyst Count
8
6
Target Price
$435.00
$40.40
AVG Volume (30 Days)
381.1K
1.4M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
3.45%
N/A
EPS Growth
N/A
132.41
EPS
12.87
25.10
Revenue
$7,414,495,000.00
$3,845,670,022.00
Revenue This Year
N/A
$24.85
Revenue Next Year
$4.21
$16.67
P/E Ratio
$27.01
$12.31
Revenue Growth
N/A
29.57
52 Week Low
$323.05
$17.24
52 Week High
$535.40
$33.65

Technical Indicators

Market Signals
Indicator
WSO
GMAB
Relative Strength Index (RSI) 48.80 59.84
Support Level $337.73 $31.32
Resistance Level $356.99 $32.41
Average True Range (ATR) 10.38 0.64
MACD 2.70 0.11
Stochastic Oscillator 73.88 73.67

Price Performance

Historical Comparison
WSO
GMAB

About WSO Watsco Inc.

Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: